title: Effect on survival of treatment-associated venous thromboembolism in newly diagnosed multiple myeloma patients.
abstract: Venous thromboembolism (VTE) is a cancer complication associated with poor survival. We have analyzed the prognostic impact of the development of a thrombotic episode in newly diagnosed multiple myeloma patients who received chemotherapy either with or without thalidomide on our Total Therapy 2 protocol. Of 668 patients enrolled, 155 developed VTE complication during treatment. The overall and event-free survival of patients who experienced VTE was not inferior. Of interest, we observed that patients who received intensive chemotherapy without thalidomide but developed a thrombosis experienced a significantly longer event-free survival compared with those without VTE (P = 0.02). Our observation suggests a possible beneficial effect of anticoagulation on survival in patients treated for myeloma.
authors: Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas 72205, USA. zangarimaurizio@uams.edu
authors: Maurizio
authors: M
authors: Zangari
authors: Bart
authors: B
authors: Barlogie
authors: Federica
authors: F
authors: Cavallo
authors: Vanessa
authors: V
authors: Bolejack
authors: Louis
authors: L
authors: Fink
authors: Guido
authors: G
authors: Tricot
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D003131:Combined Modality Therapy / Q000009:adverse effects; D018572:Disease-Free Survival; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005500:Follow-Up Studies; D006495:Heparin, Low-Molecular-Weight / Q000627:therapeutic use; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000401:mortality*; D010690:Phlebography; D011379:Prognosis; D012189:Retrospective Studies; D013792:Thalidomide / Q000627:therapeutic use; D013923:Thromboembolism / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy; D018608:Ultrasonography, Doppler; D020246:Venous Thrombosis / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D013792:Thalidomide